AJHILLER

At SciFluor, we focused on applying a proprietary fluorination chemistry technology platform from Harvard University to discover novel new drugs and imaging agents, and at Heartscape we successfully launched a novel 80-lead electrocardiogram (ECG) technology to identify heart attacks not visible to the 12-lead ECG. In three years, along with the Heartscape team, I raised more than $22 million in funding for the company, and built a Management and field sales team that successfully placed the PRIME ECG® technology in more than 30 prestigious medical institutions nationwide.